Sweeney & Michel’s AbbVie ABBV Stock Holding History

Sweeney & Michel’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.07M	Sell	10,039 -121	-1%	-$26.8K	0.61%	32
2025 Q4	$2.24M	Buy	10,160 +81	+0.8%	+$18.5K	0.66%	29
2025 Q3	$2.32M	Buy	10,079 +43	+0.4%	+$8.76K	0.78%	27
2025 Q2	$1.93M	Buy	10,036 +162	+2%	+$30.1K	0.69%	29
2025 Q1	$1.73M	Buy	+9,874	New	+$1.92M	0.76%	27
2024 Q3	$1.78M	Buy	9,426 +305	+3%	+$56.9K	0.7%	28
2024 Q2	$1.53M	Buy	9,121 +57	+0.6%	+$9.44K	0.65%	28
2024 Q1	$1.46M	Buy	+9,064	New	+$1.56M	0.65%	27
2023 Q3	$1.33M	Buy	9,378 +60	+0.6%	+$8.81K	0.7%	27
2023 Q2	$1.39M	Sell	9,318 -533	-5%	-$78.2K	0.72%	22
2023 Q1	$1.33M	Buy	+9,851	New	+$1.51M	0.71%	24

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sweeney & Michel's ABBV Position: Q1 2026 in Review

Sweeney & Michel reduced its AbbVie (ABBV) stake by 1.2% in Q1 2026, selling an estimated $26.8K and leaving 10,039 shares worth $2.07M. The position accounts for 0.61% of the portfolio, ranked #32.

Sweeney & Michel first reported a position in ABBV in Q1 2023 and has held it in 11 quarters since. The position peaked at $2.32M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Sweeney & Michel held 10,039 shares of AbbVie worth $2.07M as of Q1 2026.
Sweeney & Michel sold 121 AbbVie shares in Q1 2026, an estimated $26.8K.
AbbVie made up 0.61% of Sweeney & Michel's portfolio in Q1 2026, its #32 holding.
Sweeney & Michel first reported a position in AbbVie in Q1 2023 and has held it in 11 quarters since.
Sweeney & Michel's AbbVie position peaked at $2.32M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sweeney & Michel's 13F filing for Q1 2026, filed 16 Apr 2026.